Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bluebird Bio, Inc. (BLUE) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bluebird Bio, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1293971.
Total stock buying since 2013: $900,936.
Total stock sales since 2013: $302,744,213.
Total stock option exercises since 2013: $18,164,530.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 2,674 | $13,092 | 0 | $0 |
| 2024 | 0 | $0 | 53,225 | $32,951 | 0 | $0 |
| 2023 | 0 | $0 | 29,657 | $107,873 | 0 | $0 |
| 2022 | 0 | $0 | 60,375 | $389,963 | 0 | $0 |
| 2021 | 0 | $0 | 32,047 | $1,316,414 | 203,355 | $1,118,452 |
| 2020 | 0 | $0 | 29,953 | $2,487,840 | 600 | $30,306 |
| 2019 | 0 | $0 | 113,356 | $14,484,676 | 89,426 | $3,023,134 |
| 2018 | 0 | $0 | 253,653 | $43,940,267 | 217,526 | $4,893,932 |
| 2017 | 0 | $0 | 568,271 | $74,844,245 | 360,998 | $4,314,958 |
| 2016 | 0 | $0 | 16,898 | $789,291 | 30,986 | $183,782 |
| 2015 | 9,682 | $501,062 | 637,702 | $85,151,065 | 707,734 | $3,728,126 |
| 2014 | 6,469 | $399,874 | 2,827,352 | $78,463,786 | 431,284 | $819,211 |
| 2013 | 0 | $0 | 35,000 | $722,750 | 35,000 | $52,629 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-01-05 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,712 | 173.71 | 297,398 |
| 2018-01-03 | Davidson David (Chief Medical Officer) | Sale | 6,000 | 181.00 | 1,086,006 |
| 2018-01-03 | Davidson David (Chief Medical Officer) | Option Ex | 6,000 | 5.50 | 33,000 |
| 2018-01-03 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 180.97 | 407,193 |
| 2018-01-03 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-12-13 | Leschly Nick (President and CEO) | Sale | 117,500 | 185.03 | 21,740,907 |
| 2017-12-13 | Leschly Nick (President and CEO) | Option Ex | 37,873 | 5.50 | 208,301 |
| 2017-12-11 | Vachon Mark (Director) | Sale | 7,000 | 215.03 | 1,505,210 |
| 2017-12-11 | Vachon Mark (Director) | Option Ex | 6,000 | 30.47 | 182,820 |
| 2017-12-11 | Walsh Jeffrey T. (Chief Financial) | Sale | 9,900 | 215.92 | 2,137,588 |
| 2017-12-11 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 9,900 | 24.47 | 242,253 |
| 2017-12-01 | High Susanna Gatti (Chief Operating Officer) | Sale | 1,282 | 172.15 | 220,696 |
| 2017-12-01 | Davidson David (Chief Medical Officer) | Sale | 4,000 | 172.65 | 690,616 |
| 2017-12-01 | Davidson David (Chief Medical Officer) | Option Ex | 4,000 | 5.50 | 22,000 |
| 2017-12-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 172.74 | 388,674 |
| 2017-12-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-11-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 9,900 | 149.56 | 1,480,624 |
| 2017-11-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 9,900 | 10.69 | 105,791 |
| 2017-11-01 | Davidson David (Chief Medical Officer) | Sale | 4,000 | 145.32 | 581,276 |
| 2017-11-01 | Davidson David (Chief Medical Officer) | Option Ex | 4,000 | 5.50 | 22,000 |
| 2017-11-01 | Leschly Nick (President and CEO) | Sale | 2,127 | 145.17 | 308,778 |
| 2017-11-01 | Leschly Nick (President and CEO) | Option Ex | 2,127 | 5.50 | 11,698 |
| 2017-11-01 | Walsh Jeffrey T. (Chief Financial) | Sale | 35,000 | 151.83 | 5,313,945 |
| 2017-11-01 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 35,000 | 5.50 | 192,500 |
| 2017-11-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 144.57 | 325,280 |
| 2017-11-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-10-23 | Leschly Nick (President and CEO) | Sale | 3,700 | 145.26 | 537,454 |
| 2017-10-20 | Leschly Nick (President and CEO) | Sale | 3,350 | 145.02 | 485,813 |
| 2017-10-17 | Leschly Nick (President and CEO) | Sale | 10,823 | 145.05 | 1,569,843 |
| 2017-10-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 4,900 | 130.50 | 639,440 |
| 2017-10-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 4,900 | 5.50 | 26,950 |
| 2017-10-02 | Davidson David (Chief Medical Officer) | Sale | 4,000 | 131.44 | 525,768 |
| 2017-10-02 | Davidson David (Chief Medical Officer) | Option Ex | 4,000 | 5.50 | 22,000 |
| 2017-10-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 131.98 | 296,961 |
| 2017-10-02 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-09-14 | Maraganore John (Director) | Sale | 18,868 | 131.50 | 2,481,236 |
| 2017-09-14 | Maraganore John (Director) | Option Ex | 18,868 | 2.09 | 39,434 |
| 2017-09-12 | Vachon Mark (Director) | Sale | 6,000 | 126.57 | 759,444 |
| 2017-09-12 | Vachon Mark (Director) | Option Ex | 6,000 | 30.47 | 182,820 |
| 2017-09-11 | Walsh Jeffrey T. (Chief Financial) | Sale | 4,900 | 125.94 | 617,086 |
| 2017-09-11 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 4,900 | 5.50 | 26,950 |
| 2017-09-01 | Davidson David (Chief Medical Officer) | Sale | 12,000 | 127.59 | 1,531,092 |
| 2017-09-01 | Davidson David (Chief Medical Officer) | Option Ex | 12,000 | 5.50 | 66,000 |
| 2017-09-01 | Leschly Nick (President and CEO) | Sale | 22,500 | 130.04 | 2,925,990 |
| 2017-09-01 | Leschly Nick (President and CEO) | Option Ex | 6,364 | 5.50 | 35,002 |
| 2017-09-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 126.21 | 283,968 |
| 2017-09-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-08-31 | Leschly Nick (President and CEO) | Sale | 24,333 | 115.09 | 2,800,460 |
| 2017-08-31 | Walsh Jeffrey T. (Chief Financial) | Sale | 12,000 | 125.01 | 1,500,096 |
| 2017-08-31 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 12,000 | 5.50 | 66,000 |
| 2017-08-31 | Schenkein David P (Director) | Sale | 2,000 | 115.07 | 230,146 |
| 2017-08-31 | Schenkein David P (Director) | Option Ex | 2,000 | 8.16 | 16,312 |
| 2017-08-31 | Lynch Daniel (Director) | Sale | 500 | 120.00 | 60,000 |
| 2017-08-31 | Lynch Daniel (Director) | Option Ex | 500 | 5.50 | 2,750 |
| 2017-08-30 | Leschly Nick (President and CEO) | Sale | 25,667 | 115.18 | 2,956,299 |
| 2017-08-28 | Walsh Jeffrey T. (Chief Financial) | Sale | 1,250 | 107.06 | 133,826 |
| 2017-08-28 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 1,250 | 5.50 | 6,875 |
| 2017-08-24 | Maraganore John (Director) | Sale | 11,085 | 95.72 | 1,061,100 |
| 2017-08-24 | Maraganore John (Director) | Option Ex | 13,839 | 2.09 | 28,923 |
| 2017-08-14 | Mandell James (Director) | Sale | 1,000 | 95.95 | 95,950 |
| 2017-08-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 1,250 | 95.41 | 119,265 |
| 2017-08-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 1,250 | 5.50 | 6,875 |
| 2017-08-07 | Gregory Philip D (Chief Scientific Officer) | Sale | 750 | 99.00 | 74,250 |
| 2017-08-07 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 500 | 50.51 | 25,255 |
| 2017-08-04 | Sullivan Eric (Principal Accounting Officer) | Sale | 445 | 95.21 | 42,369 |
| 2017-08-04 | Sullivan Eric (Principal Accounting Officer) | Option Ex | 445 | 53.41 | 23,765 |
| 2017-08-03 | Sullivan Eric (Principal Accounting Officer) | Sale | 416 | 92.35 | 38,417 |
| 2017-08-03 | Sullivan Eric (Principal Accounting Officer) | Option Ex | 416 | 22.59 | 9,395 |
| 2017-08-02 | Maraganore John (Director) | Sale | 2,754 | 96.74 | 266,424 |
| 2017-08-01 | Davidson David (Chief Medical Officer) | Sale | 3,000 | 93.13 | 279,384 |
| 2017-08-01 | Davidson David (Chief Medical Officer) | Option Ex | 3,000 | 2.09 | 6,270 |
| 2017-08-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,500 | 93.14 | 139,714 |
| 2017-08-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 750 | 50.51 | 37,882 |
| 2017-07-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 2,500 | 100.19 | 250,470 |
| 2017-07-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 2,500 | 5.50 | 13,750 |
| 2017-07-07 | Davidson David (Chief Medical Officer) | Sale | 1,200 | 100.77 | 120,918 |
| 2017-07-06 | Cole Jason (Chief Legal Officer) | Option Ex | 5,126 | 22.53 | 115,488 |
| 2017-07-06 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,250 | 103.83 | 233,615 |
| 2017-07-06 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,250 | 50.51 | 63,137 |
| 2017-07-05 | Sullivan Eric (Principal Accounting Officer) | Sale | 4,313 | 107.26 | 462,608 |
| 2017-07-05 | Sullivan Eric (Principal Accounting Officer) | Option Ex | 3,580 | 37.99 | 136,022 |
| 2017-07-05 | Davidson David (Chief Medical Officer) | Sale | 5,000 | 105.66 | 528,285 |
| 2017-07-05 | Davidson David (Chief Medical Officer) | Option Ex | 5,000 | 2.09 | 10,450 |
| 2017-06-29 | Sullivan Eric (Principal Accounting Officer) | Sale | 6,787 | 109.07 | 740,230 |
| 2017-06-29 | Sullivan Eric (Principal Accounting Officer) | Option Ex | 6,728 | 31.89 | 214,576 |
| 2017-06-27 | Leschly Nick (President and CEO) | Sale | 25,000 | 108.09 | 2,702,225 |
| 2017-06-23 | Lynch Daniel (Director) | Sale | 4,000 | 109.50 | 438,016 |
| 2017-06-23 | Lynch Daniel (Director) | Option Ex | 4,000 | 3.79 | 15,172 |
| 2017-06-20 | Lynch Daniel (Director) | Sale | 2,500 | 120.03 | 300,070 |
| 2017-06-20 | Lynch Daniel (Director) | Option Ex | 2,500 | 2.09 | 5,215 |
| 2017-06-16 | Gregory Philip D (Chief Scientific Officer) | Sale | 3,295 | 109.53 | 360,914 |
| 2017-06-12 | Walsh Jeffrey T. (Chief Financial) | Sale | 2,500 | 110.26 | 275,650 |
| 2017-06-12 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 2,500 | 2.09 | 5,215 |
| 2017-06-08 | Lynch Daniel (Director) | Sale | 2,500 | 110.19 | 275,487 |
| 2017-06-08 | Lynch Daniel (Director) | Option Ex | 2,500 | 2.09 | 5,215 |
| 2017-06-07 | Cole Jason (Chief Legal Officer) | Sale | 435 | 100.05 | 43,521 |
| 2017-06-07 | Cole Jason (Chief Legal Officer) | Option Ex | 435 | 50.51 | 21,971 |
| 2017-06-06 | Walsh Jeffrey T. (Chief Financial) | Sale | 2,500 | 100.05 | 250,135 |
| 2017-06-06 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 2,500 | 2.09 | 5,215 |
| 2017-06-06 | Cole Jason (Chief Legal Officer) | Sale | 16,810 | 100.22 | 1,684,698 |
| 2017-06-06 | Cole Jason (Chief Legal Officer) | Option Ex | 16,810 | 36.52 | 613,901 |
| 2017-06-06 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,500 | 99.04 | 148,560 |
| 2017-06-06 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,000 | 50.51 | 50,510 |
| 2017-06-06 | Lynch Daniel (Director) | Sale | 2,263 | 100.14 | 226,621 |
| 2017-06-06 | Lynch Daniel (Director) | Option Ex | 2,263 | 2.09 | 4,720 |
| 2017-06-05 | Davidson David (Chief Medical Officer) | Sale | 1,000 | 90.00 | 90,002 |
| 2017-06-05 | Davidson David (Chief Medical Officer) | Option Ex | 1,000 | 2.09 | 2,090 |
| 2017-06-05 | Lynch Daniel (Director) | Sale | 1,000 | 90.00 | 90,002 |
| 2017-06-05 | Lynch Daniel (Director) | Option Ex | 1,000 | 2.09 | 2,086 |
| 2017-06-01 | Davidson David (Chief Medical Officer) | Sale | 2,000 | 75.42 | 150,850 |
| 2017-06-01 | Davidson David (Chief Medical Officer) | Option Ex | 2,000 | 2.09 | 4,180 |
| 2017-06-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,500 | 75.74 | 113,611 |
| 2017-06-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 750 | 50.51 | 37,882 |
| 2017-05-25 | Lynch Daniel (Director) | Sale | 2,000 | 80.00 | 160,002 |
| 2017-05-25 | Lynch Daniel (Director) | Option Ex | 2,000 | 2.09 | 4,172 |
| 2017-05-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 1,250 | 89.10 | 111,377 |
| 2017-05-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 1,250 | 5.50 | 6,875 |
| 2017-05-01 | Davidson David (Chief Medical Officer) | Sale | 3,000 | 88.74 | 266,220 |
| 2017-05-01 | Davidson David (Chief Medical Officer) | Option Ex | 3,000 | 2.09 | 6,270 |
| 2017-05-01 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,500 | 88.30 | 132,456 |
| 2017-05-01 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 750 | 50.51 | 37,882 |
| 2017-04-27 | Lynch Daniel (Director) | Sale | 1,000 | 90.01 | 90,010 |
| 2017-04-27 | Lynch Daniel (Director) | Option Ex | 1,000 | 2.09 | 2,086 |
| 2017-04-26 | Cole Jason (Chief Legal Officer) | Option Ex | 3,750 | 22.53 | 84,487 |
| 2017-04-25 | Lynch Daniel (Director) | Sale | 2,000 | 86.75 | 173,500 |
| 2017-04-25 | Lynch Daniel (Director) | Option Ex | 2,000 | 2.09 | 4,172 |
| 2017-04-10 | Walsh Jeffrey T. (Chief Financial) | Sale | 1,250 | 87.38 | 109,225 |
| 2017-04-10 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 1,250 | 5.50 | 6,875 |
| 2017-04-03 | Davidson David (Chief Medical Officer) | Sale | 3,000 | 91.21 | 273,633 |
| 2017-04-03 | Davidson David (Chief Medical Officer) | Option Ex | 3,000 | 2.09 | 6,270 |
| 2017-03-27 | Lynch Daniel (Director) | Sale | 1,000 | 90.00 | 90,000 |
| 2017-03-27 | Lynch Daniel (Director) | Option Ex | 1,000 | 2.09 | 2,086 |
| 2017-03-24 | Lynch Daniel (Director) | Sale | 2,000 | 87.37 | 174,732 |
| 2017-03-24 | Lynch Daniel (Director) | Option Ex | 2,000 | 2.09 | 4,172 |
| 2017-03-16 | Sullivan Eric (Principal Accounting Officer) | Sale | 411 | 99.00 | 40,689 |
| 2017-03-16 | Walsh Jeffrey T. (Chief Financial) | Sale | 3,543 | 100.07 | 354,562 |
| 2017-03-16 | Walsh Jeffrey T. (Chief Financial) | Option Ex | 3,543 | 3.79 | 13,445 |
| 2017-03-16 | Cole Jason (Chief Legal Officer) | Sale | 4,930 | 100.07 | 493,364 |
| 2017-03-16 | Cole Jason (Chief Legal Officer) | Option Ex | 4,930 | 22.53 | 111,072 |
| 2017-03-16 | Lynch Daniel (Director) | Sale | 237 | 100.07 | 23,717 |
| 2017-03-16 | Lynch Daniel (Director) | Option Ex | 237 | 2.09 | 494 |
| 2017-03-03 | Maraganore John (Director) | Sale | 13,839 | 85.02 | 1,176,647 |
| 2017-03-03 | Maraganore John (Director) | Option Ex | 13,839 | 3.22 | 44,616 |
| 2017-03-01 | Davidson David (Chief Medical Officer) | Sale | 5,000 | 89.83 | 449,155 |
| 2017-03-01 | Davidson David (Chief Medical Officer) | Option Ex | 5,000 | 2.09 | 10,450 |
| 2017-03-01 | Schenkein David P (Director) | Sale | 5,000 | 89.53 | 447,635 |
| 2017-03-01 | Schenkein David P (Director) | Option Ex | 5,000 | 8.16 | 40,780 |
| 2017-03-01 | Cole Jason (Chief Legal Officer) | Sale | 5,225 | 90.32 | 471,911 |
| 2017-03-01 | Cole Jason (Chief Legal Officer) | Option Ex | 5,225 | 50.51 | 263,914 |
| 2017-03-01 | Lynch Daniel (Director) | Sale | 2,000 | 90.32 | 180,636 |
Insider trading activities including stock purchases, stock sales, and option exercises of BLUE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bluebird Bio, Inc. (symbol BLUE, CIK number 1293971) see the Securities and Exchange Commission (SEC) website.